ACST - Acasti Pharma Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6702
-0.0072 (-6.92%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.7200
Open0.7100
Bid0.6000 x 1000
Ask0.9800 x 800
Day's Range0.6700 - 0.7180
52 Week Range0.4300 - 1.8000
Volume459,875
Avg. Volume1,452,382
Market Cap52.058M
Beta (3Y Monthly)2.34
PE Ratio (TTM)N/A
EPS (TTM)-1.2240
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
Trade prices are not sourced from all markets
  • ACCESSWIRE17 days ago

    Acasti Pharma to Present at the 11th Annual LD Micro Main Event

    Laval, Québec / ACCESSWIRE / November 27, 2018 / Acasti Pharma Inc. (ACST) (ACST) (the "Company" or "Acasti Pharma"), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the Company is scheduled to present at the 11th annual LD Micro Main Event on Wednesday, December 5 at 3:00 PM PST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Jan D'Alvise, President and Chief Executive Office, will be presenting, as well as meeting with investors.

  • Associated Presslast month

    Acasti: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Laval, Quebec-based company said it had a loss of 47 cents. Losses, adjusted for non-recurring costs and amortization costs, came to 19 cents per share. The company's shares closed ...

  • GlobeNewswirelast month

    Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019

    LAVAL, Québec, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the fiscal second quarter ended September 30, 2018. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “Following our recent capital raises in the U.S. and Canada, I am pleased to report as of November 1, we had over $52 million of cash on hand.

  • GlobeNewswirelast month

    Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call

    Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST) (the “Company” or “Acasti”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will host a conference call at 11:00 AM Eastern Time on Wednesday, November 14, 2018 to discuss the Company’s financial results for the fiscal second quarter ended September 30, 2018, as well as the Company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 877-407-8031 for U.S. callers or +1 201-689-8031 for international callers, or on the Company’s News and Investors section of the website: https://www.acastipharma.com/investors/.

  • GlobeNewswire2 months ago

    Acasti Pharma Announces Closing of C$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option

    NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. LAVAL, Quebec, Oct. 23, 2018 -- Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) (the “Company”.

  • GlobeNewswire2 months ago

    Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares

    MONTRÉAL, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced today the closing of its previously announced underwritten public offering of 16,600,000 common shares in the United States at a price to the public of $1.00 per share. In addition, the underwriters fully exercised their option to purchase 2,490,000 additional common shares at the same public offering price.  All common shares in the offering were offered by Acasti Pharma. Aegis Capital Corporation acted as a co-manager for the offering.

  • ACCESSWIRE2 months ago

    Acasti Pharma Looks Toward Phase III for CaPre with Recent Financing, Analysts Review

    NEW YORK, NY / ACCESSWIRE / October 10, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • GlobeNewswire2 months ago

    Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares

    Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced today the pricing of an underwritten public offering of 16,600,000 common shares in the United States at a price to the public of $1.00 per share. Acasti Pharma has granted the underwriters a 30-day option to purchase up to 2,490,000 additional common shares sold in the offering, to cover over-allotments, if any. All common shares in the offering are being offered by Acasti Pharma.

  • Benzinga2 months ago

    The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) AstraZeneca plc (NYSE: AZN ) Bausch Health Companies ...

  • GlobeNewswire2 months ago

    Acasti Pharma Announces Public Equity Offering

    Acasti Pharma Inc. (ACST.V) (ACST.V) (the “Company” or “Acasti”) is pleased to announce that it has filed a preliminary short form prospectus in connection with an overnight marketed public offering (the “Offering”) of common shares in the capital of the Company (“Common Shares”). The Offering will be conducted by Mackie Research Capital Corporation, as sole bookrunner and lead underwriter (the “Underwriter”).

  • GlobeNewswire2 months ago

    Acasti Pharma Announces Proposed Underwritten Public Offering of Common Shares

    MONTRÉAL, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced today that it intends to offer and sell its common shares in an underwritten public offering in the United States. Acasti Pharma intends to grant the underwriters a 30-day option to purchase additional common shares sold in the offering, to cover over-allotments, if any.  All common shares in the offering are being offered by Acasti Pharma. The proposed offering is subject to market and other conditions, including approval of the Nasdaq Capital Market and the TSX Venture Exchange.

  • Benzinga2 months ago

    The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...

  • GlobeNewswire2 months ago

    Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

    LAVAL, Québec, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced its election to issue common shares to the holders of its outstanding convertible debentures in satisfaction of interest payable. In accordance with the terms of its outstanding convertible debentures in the total aggregate principal amount of $2,000,000 issued on February 21, 2017 (the “Debentures”), the Company has elected to issue an aggregate of 23,723 common shares to the holders of the Debentures in satisfaction of an aggregate of $40,329.10 of interest payable to the holders of the Debentures, which was earned from July 1, 2018 through and payable as of September 30, 2018 (the “Interest Payment”). The common shares issuable for the Interest Payment are issuable at a price of CDN $1.70 per share, being the last closing price of the common shares on the TSX Venture Exchange before September 30, 2018.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Achieve Life Sciences and Acasti Pharma

    It was positive study results for Achieve that sent shares flying while Acasti moved on no news. Achieve Life Sciences, Inc. Achieve Life Sciences, Inc. shares were up nearly 40% yesterday on skyrocket volume.

  • GlobeNewswire3 months ago

    Acasti Pharma Appoints Jean-François Boily as Vice President of Finance

    LAVAL, Québec, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST) (the “Company” or “Acasti”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced the appointment of Jean-François Boily, CPA, as Vice President of Finance, and the planned retirement of Linda O’Keefe, Acasti’s current CFO, who will retire later this year. Prior to joining Acasti, Jean-François Boily served as a Director of Finance & Information Technology (IT) at Innovaderm Research Inc., a large North American contract research organization (CRO) specialized in dermatology. Prior to that, Mr. Boily was a Director of Finance at Teva Canada, a generic drug products manufacturer, where he oversaw manufacturing of generics, managing branded product launches and clinical R&D activities.

  • GlobeNewswire3 months ago

    Acasti Pharma Provides Clinical and Market Update

    Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a clinical and market update. “We remain very encouraged by the outlook for CaPre. Prior to commencing our Phase 3 trials, CaPre was studied in four clinical trials totaling 773 patients, a substantial patient population.

  • Associated Press4 months ago

    Acasti: 2Q Earnings Snapshot

    The Laval, Quebec-based company said it had a loss of 18 cents per share. The company's shares closed at 47 cents. A year ago, they were trading at $1.33. _____ This story was generated by Automated Insights ...

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Protalix Biotherapeutics Inc (NYSE: PLX ) stock gained ...

  • Benzinga6 months ago

    Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 27) Aptinyx Inc (NASDAQ: APTX ) Cardiovascular Systems Inc (NASDAQ: ...